Background: Use of immune checkpoint inhibitors have improved survival in patients suffering from cancer types such as advanced melanoma and NSCLC. Through increased understanding of immunological reactions associated with radiotherapy, a potential for synergy of radiotherapy and immune checkpoint inhibitors has emerged. Preclinical proof-of-concept studies have confirmed synergy of the treatments ...